Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Argenta Discovery And Porsolt Join Forces To Provide Fully-integrated CNS And Pain Contract Drug Discovery Services
Argenta Discovery and Porsolt announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for- service basis. The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination. Both companies bring a wealth of "Big Pharma" industry based experience and know-how in CNS and pain research. This alliance will leverage those key skills for its partners to ensure the rapid generation of high quality development candidates.

Response To Carotid Endarterectomy Audit
Joe Korner, Director of Communications at The Stroke Association said: "This audit shows that there is still a long way to go to make sure people get urgent preventative treatment that could prevent a catastrophic stroke.
News of the day
$29.4 Million Grant Establishes CTSI At NYU In Partnership With Health And Hospitals Corporation
NYU and NYU School of Medicine received a $29.4 million, five-year Clinical and Translational Science Award from the National Institutes of Health (NIH) to establish a University-wide Clinical & Translational Science Institute (CTSI) in partnership with the New York City Health and Hospitals Corporation (HHC). The funding is designed to train medical researchers, more rapidly advance science from the lab to the patient to the community and to allow researchers to explore mechanisms of health disparities and develop evidence-based approaches targeted at their reduction. With this grant, NYU, the NYU School of Medicine and HHC will become part of a network of 46 existing Clinical and Translational Science centers based at academic medical centers around the country.
Public Health

Early Failure Of Knee Replacements

This study investigated a series of Kinemax knee replacements where the survival rate was only 75% at nine years, compared with previously recorded rates of 96% over ten years and tried to ascertain the reason for the significantly lower survival rate. The authors discovered that on revision "the most striking feature was polyethylene wear" on the implant and therefore undertook to have the removed implants independently anaylsed for abnormalities. The findings of scanning the implants using electron microscopy were type 2 fusion defects in the polyethylene, indicating incomplete boundary fusion. Therefore, the authors "consider that the failure of the Kinemax implants in our cohort was due to material failure of the UHMWPE, probably at the time of manufacture, exacerbated by post-manufacturing oxidation". Read the full text article. The Journal of Bone and Joint Surgery


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009